A study to evaluate the safety, tolerability, and immunogenicity of a recombinant hepatitis B vaccine manufactured using an upgrade to the production process. The primary hypotheses tested at 1 month after the third dose of vaccine are the following: 1) the 3 lots of the process upgrade vaccine induce similar seroprotection rates to hepatitis B surface antigen (HBsAg), 2) the combined lots of the process upgrade vaccine induce adequate seroprotection to HBsAg, and 3) the process upgrade vaccine will induce geometric mean antibody titers to HBsAg that are non-inferior or superior to those induced by the current process vaccine.

Inclusion Criteria:

• In general good health
• Female participants have a negative pregnancy test just prior to vaccination on Day 1

Exclusion Criteria:

• History of Hepatitis B Infection or vaccination
• Known or suspected hypersensitivity to any component of Recombivax HB™ vaccine (e.g., aluminum, yeast)
• Administration of hepatitis B immune globulin, serum immune globulin, or any other blood-derived product within 3 months prior to vaccination on Day 1
• Receipt of an inactivated virus vaccine within 14 days or a live virus vaccine within 30 days prior to vaccination on Day 1
• Participation on prior study using an investigational drug or vaccine in prior 3 months
• Known or suspected impairment of immunologic function or recent use of immunomodulatory medications, excluding topical or inhaled steroids
• Pregnant or nursing women or women planning to become pregnant within the study period